The pharmaceutical giant announced profit in line with expectations and revenue that slightly beat forecasts on Tuesday.

Leon Wang, who has been in detention since 2024, was the drugmaker’s most senior executive in China for a decade until his ...

By Pushkala Aripaka, Bhanvi Satija and Maggie Fick LONDON, Feb 10 (Reuters) - AstraZeneca forecast steady profit growth in ...

Chinese prosecutors have brought formal charges against AstraZeneca and its former executives following investigations into alleged illegal patient data collection and importation of drugs. | Chinese ...

CEO Pascal Soriot said in a call with reporters on Tuesday that the group’s confidence in reaching $80 billion in revenue in ...

AstraZeneca has reported a robust rise in revenue in 2025, driven by strong demand for its cancer medicines, and struck an ...

AstraZeneca is taking its oral GLP-1 drug into phase 3 on the back of a pair of midstage weight loss wins, despite remaining ...

Feb 11 (Reuters) - China has officially charged AstraZeneca's former regional head, Leon Wang, who was detained by ...

AstraZeneca announces multibillion dollar investments in China as Big Pharma is increasingly looking east for innovation.

There is a history of studying relaxin in cardiovascular settings—Novartis started a phase 3 heart failure trial of a recombinant relaxin-2 peptide in 2013—but preclinical evidence of the molecule’s ...

After ending 2025 with a strong fourth quarter, AstraZeneca management has doubled down on its ambitious “$80 billion by 2030 ...

Feb 11 (Reuters) - China has officially charged AstraZeneca's former head of the business in the country, Leon Wang, who had been in detention since October 2024, the drugmaker confirmed to Reuters on ...